1346242-81-6ERDAFITINIB
121 Inquiries
1346242-81-6
pharmaceutical grade
99%
1
Ipure
25kg/Cardboard Drum
2026-04-12
pharmaceutical intermediates,chemical
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine
Other Name:1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9
CAS No.:1346242-81-6
Molecular Formula:C25H30N6O2
InChIKeys:InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N
Molecular Weight:446.54
Exact Mass:446.54
UNII:890E37NHMV
NCI Thesaurus Code:C103273
ATC Code:L - Antineoplastic and immunomodulating agents
Categories:
Characteristics-
PSA:
77.3
XLogP3:3.2
Density:1.2±0.1 g/cm3
Flash Point:354.4±31.5 °C
Refractive Index:1.618
Water Solubility:<1 mg/mL
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Skin sensitization, Sub-category 1B
Serious eye damage, Category 1
Reproductive toxicity, Category 2
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H317 May cause an allergic skin reaction
H318 Causes serious eye damage
H361 Suspected of damaging fertility or the unborn child
H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P203 Obtain, read and follow all safety instructions before use.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P333+P317 If skin irritation or rash occurs: Get medical help.
P321 Specific treatment (see ... on this label).
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P317 Get medical help.
P318 IF exposed or concerned, get medical advice.
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
pharmaceutical intermediates,chemical
-
Location:
Company Office Address: Room 1508, 15/F, Yate Centre Office Tower 2, 625 Nathan Road, Mong Kok, Hong Kong
-
Payment Terms:
TT against copy of documents,D/P,L/C,O/A,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History121 Inquiries
Country Product Purchase Quantity Date Posted
United States
Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price
3 MT Jul 5, 2026
Australia
Erdafitinib
1 G Jul 18, 2026
Bulgaria
Erdafitinib
500 MG Jun 18, 2026
Switzerland
1g Erdafitinib raw powder >99% purity
1 G May 22, 2026
Cyprus
Erdafitinib
1 G Jul 18, 2026
United Kingdom
Erdafatinib
1 G Jul 18, 2026
Switzerland
Erdafitnib
1 G Jul 18, 2026
Ireland
Erdafitinib
1 G Jul 13, 2026
United States
Erdafitinib
1 G Jul 13, 2026
Brazil
High Quality Erdafitinib 99% powder 1346242-81-6-Shaanxi Dideu Medichem Co.Ltd
1 G Jul 12, 2026
Indonesia
Erdafitinib
1 G Jul 9, 2026
United States
Erdafitinib
1 G Jul 9, 2026
United States
Erdafitinib
1 G Jul 2, 2026
United States
Erdafitinib
1 G Jul 2, 2026
United States
Erdafitinib
1 G Jul 2, 2026
United Kingdom
erdafitinib
5 KG Jul 1, 2026
Mexico
Erdafitinib powder
10 G Jun 30, 2026
United States
Erdafitinib
1 G Jun 29, 2026
Norway
Erdafitinib
1 G Jun 29, 2026
United States
EDRAFITINIB
1 KG Jun 28, 2026 Post an enquiry for this product